Wilex (Germany)

Recent papers from Wilex (Germany)

1. Effect of Severe Renal Impairment on Pharmacokinetics, Safety, and Tolerability of ACT‐1014‐6470, a Novel Oral Complement Factor 5a Receptor 1 AntagonistClinical Pharmacology in Drug Development · 2022
2. Efficacy and safety of cotadutide, a dual glucagon‐like peptide‐1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney diseaseDiabetes Obesity and Metabolism · 2022
3. Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037Cancer Chemotherapy and Pharmacology · 2016
4. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell CarcinomaJAMA Oncology · 2016
5. Monoclonal antibody G250 targeting CA IX: Binding specificity, internalization and therapeutic effects in a non-renal cancer modelInternational Journal of Oncology · 2014
6. Retrospective Evaluation of Efficiency and Safety of an Anterior Percutaneous Approach for Cervical DiscectomyAsian Spine Journal · 2014
7. Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancerBritish Journal of Cancer · 2013
8. Activation of the anti-cancer agent upamostat by the mARC enzyme systemXenobiotica · 2013
9. Circulating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients?Biomarkers in Cancer · 2013
10. Urokinase-Type Plasminogen Activator Promotes Paracellular Transmigration of Neutrophils Via Mac-1, But Independently of Urokinase-Type Plasminogen Activator ReceptorCirculation · 2011
11. Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1Expert Review of Molecular Diagnostics · 2011
12. Multimodal therapy for synergic inhibition of tumour cell invasion and tumour-induced angiogenesisBMC Cancer · 2010
13. The Oral Serine Protease Inhibitor WX-671 – First Experience in Patients with Advanced Head and Neck CarcinomaBreast Care · 2008
14. The Role of uPA and uPA Inhibitors in Breast CancerBreast Care · 2008
15. Small, Potent, and Selective Diaryl Phosphonate Inhibitors for Urokinase-Type Plasminogen Activator with In Vivo Antimetastatic PropertiesJournal of Medicinal Chemistry · 2007
16. Targeting of Biliary Cancer with Radiolabeled Chimeric Monoclonal Antibody CG250Cancer Biotherapy and Radiopharmaceuticals · 2006
17. A Clinical Trial With Chimeric Monoclonal Antibody WX-G250 and Low Dose Interleukin-2 Pulsing Scheme for Advanced Renal Cell CarcinomaThe Journal of Urology · 2005
18. Radioimmunotherapy with [131I]cG250 in Patients with Metastasized Renal Cell Cancer: Dosimetric Analysis and Immunologic ResponseClinical Cancer Research · 2005
19. Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1Thrombosis and Haemostasis · 2005
20. Inhibition of the invasion capacity of carcinoma cells by WX‐UK1, a novel synthetic inhibitor of the urokinase‐type plasminogen activator systemInternational Journal of Cancer · 2004